Yuichiro Yano1, Jared P Reis2, Laura A Colangelo3, Daichi Shimbo4, Anthony J Viera1, Norrina B Allen3, Samuel S Gidding5, Adam P Bress6, Philip Greenland3, Paul Muntner7, Donald M Lloyd-Jones3. 1. Department of Community and Family Medicine, Duke University, Durham, North Carolina. 2. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 3. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 4. Department of Medicine, Columbia University Medical Center, New York, New York. 5. Nemours Cardiac Center, Alfred I. DuPont Hospital for Children, Wilmington, Delaware. 6. Division of Health System Innovation and Research, Department of Population Health Sciences, University of Utah, Salt Lake City. 7. Department of Epidemiology, University of Alabama at Birmingham, Birmingham.
Abstract
Importance: Little is known regarding the association between level of blood pressure (BP) in young adulthood and cardiovascular disease (CVD) events by middle age. Objective: To assess whether young adults who developed hypertension, defined by the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) BP guideline, before age 40 years have higher risk for CVD events compared with those who maintained normal BP. Design, Setting, and Participants: Analyses were conducted in the prospective cohort Coronary Artery Risk Development in Young Adults (CARDIA) study, started in March 1985. CARDIA enrolled 5115 African American and white participants aged 18 to 30 years from 4 US field centers (Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California). Outcomes were available through August 2015. Exposures: Using the highest BP measured from the first examination to the examination closest to, but not after, age 40 years, each participant was categorized as having normal BP (untreated systolic BP [SBP] <120 mm Hg and diastolic BP [DBP] <80 mm Hg; n = 2574); elevated BP (untreated SBP 120-129 mm Hg and DBP <80 mm Hg; n = 445); stage 1 hypertension (untreated SBP 130-139 mm Hg or DBP 80-89 mm Hg; n = 1194); or stage 2 hypertension (SBP ≥140 mm Hg, DBP ≥90 mm Hg, or taking antihypertensive medication; n = 638). Main Outcomes and Measures: CVD events: fatal and nonfatal coronary heart disease (CHD), heart failure, stroke, transient ischemic attack, or intervention for peripheral artery disease (PAD). Results: The final cohort included 4851 adults (mean age when follow-up for outcomes began, 35.7 years [SD, 3.6]; 2657 women [55%]; 2441 African American [50%]; 206 taking antihypertensive medication [4%]). Over a median follow-up of 18.8 years, 228 incident CVD events occurred (CHD, 109; stroke, 63; heart failure, 48; PAD, 8). CVD incidence rates for normal BP, elevated BP, stage 1 hypertension, and stage 2 hypertension were 1.37 (95% CI, 1.07-1.75), 2.74 (95% CI, 1.78-4.20), 3.15 (95% CI, 2.47-4.02), and 8.04 (95% CI, 6.45-10.03) per 1000 person-years, respectively. After multivariable adjustment, hazard ratios for CVD events for elevated BP, stage 1 hypertension, and stage 2 hypertension vs normal BP were 1.67 (95% CI, 1.01-2.77), 1.75 (95% CI, 1.22-2.53), and 3.49 (95% CI, 2.42-5.05), respectively. Conclusions and Relevance: Among young adults, those with elevated blood pressure, stage 1 hypertension, and stage 2 hypertension before age 40 years, as defined by the blood pressure classification in the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, had significantly higher risk for subsequent cardiovascular disease events compared with those with normal blood pressure before age 40 years. The ACC/AHA blood pressure classification system may help identify young adults at higher risk for cardiovascular disease events.
Importance: Little is known regarding the association between level of blood pressure (BP) in young adulthood and cardiovascular disease (CVD) events by middle age. Objective: To assess whether young adults who developed hypertension, defined by the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) BP guideline, before age 40 years have higher risk for CVD events compared with those who maintained normal BP. Design, Setting, and Participants: Analyses were conducted in the prospective cohort Coronary Artery Risk Development in Young Adults (CARDIA) study, started in March 1985. CARDIA enrolled 5115 African American and white participants aged 18 to 30 years from 4 US field centers (Birmingham, Alabama; Chicago, Illinois; Minneapolis, Minnesota; and Oakland, California). Outcomes were available through August 2015. Exposures: Using the highest BP measured from the first examination to the examination closest to, but not after, age 40 years, each participant was categorized as having normal BP (untreated systolic BP [SBP] <120 mm Hg and diastolic BP [DBP] <80 mm Hg; n = 2574); elevated BP (untreated SBP 120-129 mm Hg and DBP <80 mm Hg; n = 445); stage 1 hypertension (untreated SBP 130-139 mm Hg or DBP 80-89 mm Hg; n = 1194); or stage 2 hypertension (SBP ≥140 mm Hg, DBP ≥90 mm Hg, or taking antihypertensive medication; n = 638). Main Outcomes and Measures: CVD events: fatal and nonfatal coronary heart disease (CHD), heart failure, stroke, transient ischemic attack, or intervention for peripheral artery disease (PAD). Results: The final cohort included 4851 adults (mean age when follow-up for outcomes began, 35.7 years [SD, 3.6]; 2657 women [55%]; 2441 African American [50%]; 206 taking antihypertensive medication [4%]). Over a median follow-up of 18.8 years, 228 incident CVD events occurred (CHD, 109; stroke, 63; heart failure, 48; PAD, 8). CVD incidence rates for normal BP, elevated BP, stage 1 hypertension, and stage 2 hypertension were 1.37 (95% CI, 1.07-1.75), 2.74 (95% CI, 1.78-4.20), 3.15 (95% CI, 2.47-4.02), and 8.04 (95% CI, 6.45-10.03) per 1000 person-years, respectively. After multivariable adjustment, hazard ratios for CVD events for elevated BP, stage 1 hypertension, and stage 2 hypertension vs normal BP were 1.67 (95% CI, 1.01-2.77), 1.75 (95% CI, 1.22-2.53), and 3.49 (95% CI, 2.42-5.05), respectively. Conclusions and Relevance: Among young adults, those with elevated blood pressure, stage 1 hypertension, and stage 2 hypertension before age 40 years, as defined by the blood pressure classification in the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, had significantly higher risk for subsequent cardiovascular disease events compared with those with normal blood pressure before age 40 years. The ACC/AHA blood pressure classification system may help identify young adults at higher risk for cardiovascular disease events.
Authors: Russell V Luepker; Fred S Apple; Robert H Christenson; Richard S Crow; Stephen P Fortmann; David Goff; Robert J Goldberg; Mary M Hand; Allan S Jaffe; Desmond G Julian; Daniel Levy; Teri Manolio; Shanthi Mendis; George Mensah; Andrzej Pajak; Ronald J Prineas; K Srinath Reddy; Veronique L Roger; Wayne D Rosamond; Eyal Shahar; A Richey Sharrett; Paul Sorlie; Hugh Tunstall-Pedoe Journal: Circulation Date: 2003-11-10 Impact factor: 29.690
Authors: Yuichiro Yano; Jared P Reis; Yacob G Tedla; David C Goff; David R Jacobs; Stephen Sidney; Hongyan Ning; Kiang Liu; Philip Greenland; Donald M Lloyd-Jones Journal: JAMA Cardiol Date: 2017-04-01 Impact factor: 14.676
Authors: Donald M Lloyd-Jones; Yuling Hong; Darwin Labarthe; Dariush Mozaffarian; Lawrence J Appel; Linda Van Horn; Kurt Greenlund; Stephen Daniels; Graham Nichol; Gordon F Tomaselli; Donna K Arnett; Gregg C Fonarow; P Michael Ho; Michael S Lauer; Frederick A Masoudi; Rose Marie Robertson; Véronique Roger; Lee H Schwamm; Paul Sorlie; Clyde W Yancy; Wayne D Rosamond Journal: Circulation Date: 2010-01-20 Impact factor: 29.690
Authors: Yuichiro Yano; Jeremiah Stamler; Daniel B Garside; Martha L Daviglus; Stanley S Franklin; Mercedes R Carnethon; Kiang Liu; Philip Greenland; Donald M Lloyd-Jones Journal: J Am Coll Cardiol Date: 2015-02-03 Impact factor: 24.094
Authors: Michael Domanski; Gary Mitchell; Marc Pfeffer; James D Neaton; James Norman; Kenneth Svendsen; Richard Grimm; Jerome Cohen; Jeremiah Stamler Journal: JAMA Date: 2002 May 22-29 Impact factor: 56.272
Authors: April P Carson; Cora E Lewis; David R Jacobs; Carmen A Peralta; Lyn M Steffen; Julie K Bower; Sharina D Person; Paul Muntner Journal: Hypertension Date: 2013-09-16 Impact factor: 10.190
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Chike C Nwabuo; Duke Appiah; Henrique T Moreira; Henrique D Vasconcellos; Queen N Aghaji; Bharath Ambale-Venkatesh; Jamal S Rana; Norrina B Allen; Donald M Lloyd-Jones; Pamela J Schreiner; Samuel S Gidding; João A C Lima Journal: Am J Med Date: 2020-01-27 Impact factor: 4.965
Authors: Victor W Zhong; Linda Van Horn; Marilyn C Cornelis; John T Wilkins; Hongyan Ning; Mercedes R Carnethon; Philip Greenland; Robert J Mentz; Katherine L Tucker; Lihui Zhao; Arnita F Norwood; Donald M Lloyd-Jones; Norrina B Allen Journal: JAMA Date: 2019-03-19 Impact factor: 56.272
Authors: John Henry Dasinger; Ammar J Alsheikh; Justine M Abais-Battad; Xiaoqing Pan; Daniel J Fehrenbach; Hayley Lund; Michelle L Roberts; Allen W Cowley; Srividya Kidambi; Theodore A Kotchen; Pengyuan Liu; Mingyu Liang; David L Mattson Journal: Hypertension Date: 2019-12-16 Impact factor: 10.190